Lofexidine
Top View
- Lucemyra (Lofexidine Hcl)
- Respect Reason Recognition Resolution Referral Respect
- Combined Use of Trazodone-Naltrexone Versus Clonidine-Naltrexone in Rapid Withdrawal from Methadone Treatment
- Cognitive Enhancement As a Pharmacotherapy Target For
- Systematic Review of the Safety of Buprenorphine, Methadone and Naltrexone
- Yale University School of Medicine
- CCHCS Care Guide: Hypertension
- Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy In
- Alpha2-Adrenergic Agonists for the Reduction Or Discontinuation of Opioids Or Opioid Substitution Therapy: a Review of Clinical Effectiveness and Guidelines
- Medication Management for Chronic Pain: the Pharmacist’S Perspective
- LUCEMYRA Safely and Effectively
- Effects of the Alpha-2 Adrenergic Receptor Agonist Lofexidine On
- LUCEMYRA (Lofexidine) RATIONALE for INCLUSION in PA PROGRAM
- Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine
- LUCEMYRA (Lofexidine)
- Metharose® Sugar Free 1Mg/1Ml Oral Solution Methadone Hydrochloride
- Implementing Antagonist- Based Relapse Prevention Treatment for Buprenorphine- Treated Individuals
- Lucemyra) Reference Number: CP.PMN.152 Effective Date: 07.31.18 Last Review Date: 08.19 Line of Business: Commercial, HIM, Medicaid Revision Log